Clinical Trial Detail

NCT ID NCT03927261
Title PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

PRGN-3006

Age Groups: senior adult

No variant requirements are available.